Pulmatrix Stock Fundamentals
| PULM Stock | USD 6.29 0.25 4.14% |
Pulmatrix fundamentals help investors to digest information that contributes to Pulmatrix's financial success or failures. It also enables traders to predict the movement of Pulmatrix Stock. The fundamental analysis module provides a way to measure Pulmatrix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pulmatrix stock.
At this time, Pulmatrix's Net Interest Income is very stable compared to the past year. Pulmatrix | Select Account or Indicator |
Pulmatrix Company Return On Equity Analysis
Pulmatrix's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pulmatrix Return On Equity | -0.59 |
Most of Pulmatrix's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pulmatrix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Pulmatrix Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Pulmatrix has a Return On Equity of -0.5899. This is 97.54% lower than that of the Pharmaceuticals sector and 98.38% lower than that of the Health Care industry. The return on equity for all United States stocks is 90.29% higher than that of the company.
Pulmatrix Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pulmatrix's current stock value. Our valuation model uses many indicators to compare Pulmatrix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pulmatrix competition to find correlations between indicators driving Pulmatrix's intrinsic value. More Info.Pulmatrix is regarded fourth in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . At this time, Pulmatrix's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pulmatrix by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Pulmatrix Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pulmatrix's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pulmatrix could also be used in its relative valuation, which is a method of valuing Pulmatrix by comparing valuation metrics of similar companies.Pulmatrix is currently under evaluation in return on equity category among its peers.
Pulmatrix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pulmatrix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pulmatrix's managers, analysts, and investors.Environmental | Governance | Social |
Pulmatrix Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.95) % | ||||
| Operating Margin | (3.80) % | ||||
| Current Valuation | 11.28 M | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Institutions | 7.16 % | ||||
| Number Of Shares Shorted | 7.05 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 1.94 X | ||||
| Revenue | 7.3 M | ||||
| Gross Profit | 6.07 M | ||||
| EBITDA | (13.27 M) | ||||
| Net Income | (14.12 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 8.76 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.19 X | ||||
| Book Value Per Share | 4.93 X | ||||
| Cash Flow From Operations | (15.98 M) | ||||
| Short Ratio | 0.75 X | ||||
| Earnings Per Share | (2.64) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 22 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 22.06 M | ||||
| Total Asset | 33.96 M | ||||
| Retained Earnings | (287.6 M) | ||||
| Working Capital | 16.93 M | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
| Net Asset | 33.96 M |
About Pulmatrix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pulmatrix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmatrix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmatrix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 618 K | 648.9 K | |
| Total Revenue | 7.3 M | 3.9 M | |
| Cost Of Revenue | 15.5 M | 10.8 M | |
| Stock Based Compensation To Revenue | 0.13 | 0.12 | |
| Sales General And Administrative To Revenue | 0.89 | 0.85 | |
| Research And Ddevelopement To Revenue | 2.13 | 2.02 | |
| Capex To Revenue | 0.09 | 0.18 | |
| Revenue Per Share | 2.00 | 1.90 | |
| Ebit Per Revenue | (2.02) | (2.12) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Pulmatrix Piotroski F Score and Pulmatrix Altman Z Score analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.